Newsletter | September 11, 2020

09.11.20 -- How Has COVID-19 Stalled Drug Development?

Magazine Articles
Companies To Watch: CalciMedica

“In a sense, the COVID-19 association was a golden opportunity for our drug,” says Rachel Leheny, CEO of CalciMedica, a pharma focused on anti-inflammatories for pancreatitis that has now shifted to treatments for COVID-19 pneumonia.

What To Know About Patents For Software As A Medical Device

The FDA treats machine learning and AI in software used by the patient as a medical device (SaMD). If clinical trials are required, then any patent on the software may be entitled to a patent terms extension (PTE) to compensate for the time lost in the clinical testing and regulatory review.

Creating Positive Connections In The Virtual World

As more people live in the virtual world and connect by mobile devices and computers, we must learn and understand how to create enduring connections and meaningful relationships.

Life Science Connect Podcast

Our in-house editors have informal discussions about some of the hot topics they’re writing about, interesting interviews they’ve had recently with top industry executives, and what they learned during their recent travels to trade shows and conferences.

How Has COVID-19 Stalled Drug Development

In this video segment, Jeremy Levin, D.Phil., MB BChir, CEO, Ovid Therapeutics and Ted Love, M.D., CEO of Global Blood Therapeutics discuss how the pandemic has stalled some drug development efforts. 

September 2020 Digital Edition

Inside you will find more on:

  • Due Diligence And MiMedx's CEO
  • Drug Price Evaluations
  • Ask The Board
  • Industry Research

View the digital edition.

Contribute To Life Science Leader
Article Submission Guidelines

Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director.